https://cftrsignaling.com/macr....ophage-ablation-subs
Caplacizumab therapy led to a substantial acceleration in platelet count recovery, with 35 patients (IQR, 2–6 days) achieving normalization compared to 16 days (IQR, 95-235 days) in a historical control group (p = .002). The median number of plasma exchanges and the duration in days needed for these exchanges varied considerably between the caplacizumab group and the historical control group. The caplacizumab group showed a median of 6
লাইক
মন্তব্য করুন
শেয়ার করুন
